hepatocytes from man, Sprague–Dawley rat, minipig, and beagle dog. Chem Biol
Interact 2001;134:271–281.
Luo G, Cunningham M, Kim S, Burn T, Lin J, Sinz M, Hamilton G, Rizzo C, Jolley S,
Gilbert D, Downey A, Mudra D, Graham R, Carroll K, Xie J, Madan A, Parkinson
A, Christ D, Selling B, LeCluyse E, Gan LS. CYP3A4 induction by drugs:
correlation between a pregnane X receptor reporter gene assay and CYP3A4
expression in human hepatocytes. Drug Metab Dispos 2002;30:795–804.
Luo G, Guenthner T, Gan LS, Humphreys WG. CYP3A4 induction by xenobiotics:
biochemistry, experimental methods and impact on drug discovery and development.
Curr Drug Metab 2004;5:483–505.
Luo G, Lin J, Fiske WD, Dai R, Yang TJ, Kim S, Sinz M, LeCluyse E, Solon E,
Brennan JM, Benedek IH, Jolley S, Gilbert D, Wang L, Lee FW, Gan LS.
Concurrent induction and mechanism-based inactivation of CYP3A4 by an L-
valinamide derivative. Drug Metab Dispos 2003;31:1170–1175.
Matsuda H, Kinoshita K, Sumida A, Takahashi K, Fukuen S, Fukuda T, Yamamoto I,
Azuma J. Taurine modulates induction of cytochrome P450 3A4 mRNA by
rifampicin in the HepG2 cell line. Biochim Biophys Acta 2002;1593:93–98.
Matsuura Y, Kotani E, Iio T, Fukuda T, Tobinaga S, Yoshida T, Kuroiwa Y.
Structure-activity relationships in the induction of hepatic microsomal cytochrome
P450 by clotrimazole and its structurally related compounds in rats. Biochem
Pharmacol 1991;41:1949–1956.
McCune JS, Hawke RL, LeCluyse EL, Gillenwater HH, Hamilton G, Ritchie J, Lindley
C.In vivoandin vitroinduction of human cytochrome P4503A4 by dexamethasone.
Clin Pharmacol Ther 2000;68:356–366.
Meunier V, Bourrie M, Julian B, Marti E, Guillou F, Berger Y, Fabre G. Expression
and induction of CYP1A1/1A2, CYP2A6 and CYP3A4 in primary cultures of
human hepatocytes: a 10-year follow-up. Xenobiotica 2000;30:589–607.
Mills JB, Rose KA, Sadagopan N, Sahi J, de Morais SM. Induction of drug metabolism
enzymes and MDR1 using a novel human hepatocyte cell line. J Pharmacol Exp Ther
2004;309:303–309.
Moore JT, Kliewer SA. Use of the nuclear receptor PXR to predict drug interactions.
Toxicology 2000;153:1–10.
Moore JT, Moore LB, Maglich JM, Kliewer SA. Functional and structural comparison
of PXR and CAR. Biochim Biophys Acta 2003;1619:235–238.
Moore LB, Maglich JM, McKee DD, Wisely B, Willson TM, Kliewer SA, Lambert
MH, Moore JT. Pregnane X receptor (PXR), constitutive androstane receptor
(CAR), and benzoate X receptor (BXR) define three pharmacologically distinct
classes of nuclear receptors. Mol Endocrinol 2002;16:977–986.
Mouly S, Lown KS, Kornhauser D, Joseph JL, Fiske WD, Benedek IH, Watkins PB.
Hepatic but not intestinal CYP3A4 displays dose-dependent induction by efavirenz
in humans. Clin Pharmacol Ther 2002;72:1–9.
Nebert DW, Puga A, Vasiliou V. Role of the Ah receptor and the dioxin-inducible [Ah]
gene battery in toxicity, cancer, and signal transduction. Ann N Y Acad Sci
1993;685:624–640.
Okey AB. Enzyme induction in the cytochrome P-450 system. Pharmacol Ther
1990;45:241–298.
REFERENCES 569